CVKD Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 31.32%, SMA50 16.53%, SMA200 -25.56%). The stock’s 14-day RSI is 62.94 (firm momentum), while the ATR of 0.72 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.41% below its high and over 70.67% above its low. Average 10-day trading volume of 60.95 thousand shares is slightly above the 3-month average of 52.41 thousand, indicating heightened recent market interest.

Wall Street analysts project EPS growth of 35.34% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $13.00. The high target offers 94.9% upside. The low target suggests 94.9% downside. The mean target is $13.00. This offers 94.9% upside. Cadrenal Therapeutics, Inc. Common Stock earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 31, 2026, missed forecasts by 20.51%. The prior quarter beat by -15.48%. Over the last six quarters, Apple has recorded several small beats. These include 12.95% in November 07, 2024.

Cadrenal Therapeutics, Inc. Common Stock has 2.05 million shares outstanding. The public float is 1.48 million shares, elevated short interest at 0.73% of float. This equals 11.32 thousand shares. The short ratio is 0.36 days. Institutional investors hold 10.02% of the float. Insiders own 27.84%. MURPHY JOHN RAYMOND holds 614.79 thousand shares, Pham Quang X has 196.09 thousand shares and Szot Matthew K has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 9.93 thousand shares across 1 transactions.

Cadrenal Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.01. This means the shares are trading above this model’s fair value.

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD) closed at $6.35 USD, losing -$0.32 (-4.80%) from the previous close of $6.67. The stock is currently mid-range between its 52-week high and low $4.21 and $16.75. With a market capitalization of about $15.92 million, Cadrenal Therapeutics, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~1.55). Key stats such as the average daily volume over the past year has been around 52.06 thousand shares, trading with heavier-than-usual volume. Headquartered in Ponte Vedra, FL, Cadrenal Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Quang X. Pham, the company employs approximately 4 people and listed since January 20, 2023. Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.

Cadrenal Therapeutics, Inc. Common Stock trades at a P/E ratio of -0.98, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.74 trading at moderately above to book value. The P/FCF stands at -1.3, also below market averages.

Our AI price prediction model suggests that Cadrenal Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.2%, with price expected at $6.59 by May 14, 2026, within a range of $6.11 to $7.09 3-Month Outlook: Projected fall of -46.93%, reaching $3.54 by July 29, 2026, with a range of $3.11 to $3.94. 1-Year Outlook: Projected loss of -68.97%, with price at $2.07 by April 30, 2027, within a range of $0.00 to $0.00.

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD) shares are flat 8.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cadrenal Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -0.98. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.67, suggesting 0.0% downside. Our AI forecast model points to short-term weakness (-1.2% over two weeks), a medium-term fall (-46.93% over three months), and a longer-term loss (-68.97% over one year), with expected trading ranges indicating moderate volatility.